Home / News / Global Biosimilars Market is expected to grow at the CAGR of 22.6% during 2015-2022 – Brisk Insights

Global Biosimilars Market is expected to grow at the CAGR of 22.6% during 2015-2022 – Brisk Insights

According to a recently published report, the Biosimilars Market is expected to grow at the CAGR of 22.6% during 2015-2022. The segmentation of global biosimilars market is based on product type, application, technology, services and geography. The report on Global Biosimilars Market Forecast, 2015-2022 (by product type, application, technology, services and geography) provides detailed overview and predictive analysis of the market.
Full report available Global Biosimilars Market Forecast, 2015-2022 (by product type, application, technology, services and geography) report at http://www.briskinsights.com/report/biosimilars-market
Increasing number of off patented drugs, rising pressure to decrease healthcare expenditure and cost effectiveness are the various factors that are driving the growth of global biosimilars market. Market players are implementing various growth strategies in the market to gain a competitive edge. New product launch, product pipelines, agreements and collaborations were certain major strategies adopted by players. Some of the challenges faced by biosimilars market are fledgling regulatory framework and various manufacturing related issues.
Scope of the report

1. Global Biosimilar market by product type, 2012 – 2022 ($ billion)
1.1. Recombinant Peptides
1.1.1. Glucagon
1.1.2. Calcitonin
1.2. Recombinant Glycosylated Proteins
1.2.1. Erythropoietin (EPO)
1.2.2. Follitropin
1.2.3. Monoclonal Antibodies (MABS)
1.3. Recombinant Non-Glycosylated Proteins
1.3.1. Interferons
1.3.2. Recombinant Human Growth Hormone (RHGH)
1.3.3. Granulocyte Colony-Stimulating Factor (Filgrastim)
1.3.4. Insulin

2. Global Biosimilar market by application type, 2012 – 2022 ($ billion)
2.1. Blood Disorders
2.2. Chronic and Autoimmune Diseases
2.3. Growth Hormone Deficiency
2.4. Infectious Diseases
2.5. Other Applications

3. Global Biosimilar market by technology, 2012 – 2022 ($ billion)
3.1. Nuclear magnetic resonance technology
3.2. Western blotting
3.3. Monoclonal antibodies technology
3.4. Electrophoresis
3.5. Chromatography
3.6. Bioassay
3.7. Recombinant DNA technology
3.8. Mass spectrometry

4. Global Biosimilar market by technology, 2012 – 2022 ($ billion)
4.1. Clinical trials
4.2. Contract research & manufacturing services (CRMS)

5. Global Biosimilar market , regional outlook, 2012-2022(in $billion)
5.1. North America
5.2. Europe
5.3. Asia Pacific
5.4. Middle East & Africa
5.5. Latin America
6. Company profiles
6.1. Amgen
6.2. Biocon Ltd.
6.3. Celltrion, Inc.
6.4. Dr. Reddy’s Laboratories
6.5. Hospira,inc
6.6. Merck KGAA
6.7. Mylan, Inc.
6.8. Roche Diagnostics
6.9. Sandoz International GmbH
6.10. Teva Pharmaceutical Industries Ltd.
6.11. Stada Arzneimittel AG
6.12. Ratiopharm GmbH
6.13. Intas Pharmaceuticals Ltd.
6.14. LG Life Sciences
6.15. Synthon Pharmaceuticals, Inc.

Global Biosimilars Market is expected to grow at the CAGR of 22.6% during 2015-2022 – Brisk Insights reviewed on April 26, 2016 by rated 4.7 of 5

Release ID: 1814

About Anuradha Shukla

Check Also

400-400

Global Pharmacovigilance Market to Worth USD 5.9 Bn by 2022 – Credence Research

According to the latest report published by Credence Research, Inc. “Global Pharmacovigilance Market – Growth, ...